Cenix BioScience this week announced that it has signed an agreement to provide its research services to Swiss drugmaker Debiopharm.

Under the deal, Cenix will use its high-throughput screening and high-content assay know-how to identify predictive biomarkers for Debiopharm’s preclinical oncology candidates.

“Multi-parametric microscopy-based readouts established by Cenix … will be used in a range of human cancer cell models to identify genes and pathways that either enhance or suppress the drug's therapeutic effects,” the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.